Skip to Main content Skip to Navigation
Master Thesis

Devenir des personnes vivant avec le VIH sous une association TRIO dans la cohorte Aquitaine ANRS CO3 : vers une stratégie de simplification thérapeutique ?

Abstract : Objectives: to assess the long-term follow-up of patients in the ANRS CO3 Aquitaine Cohort treated with a regimen containing etravirine, raltegravir and boosted darunavir (TRIO regimen). Methods: patients from the ANRS CO3 Aquitaine Cohort who were prescribed d a TRIO regimen between February 2007 and September 2018 were included in the present analysis. The primary endpoint was the proportion of patients experiencing virological failure (VF), defined as two plasma viral load (pVL) >50 copies/mL after 24 weeks on the TRIO combination. The secondary endpoints assessed the long-term virological follow-up and the proportion of patients who had a treatment simplification. Results: one hundred and thirty-six patients were included. Baseline plasma viral load (pVL) was above 50 copies /mL for 92(67.6%) patients and below 50 copies /mL for 44 (32.4%). Baseline cumulative resistance genotype showed that 40.8% of patients were resistant to etravirine, 16% to darunavir/ritonavir twice daily and 1.4% to raltegravir Twenty-nine (30.2%) patients experienced VF with resistance associated mutations mainly detected on integrase. The median duration of the follow-up was 7.8 years (InterQuartile Range, 4-9.6) and 27 (19.9%) patients died, including 19 (13.8%) patients under the TRIO regimen. At the last visit, 9 (8.3%) patients were still receiving the TRIO regimen. In opposition, 55 (40.4%) were simplified to dual therapy and 1 (0.7%) to PI-monotherapy. Overall, 96.2% of these patients were virologically suppressed. Conclusion: the long-term virological outcomes were favorable in patients treated with the TRIO regimen, half of them having been eligible for drug-reducing strategies.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [93 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-02517436
Contributor : Bu Carreire Université de Bordeaux <>
Submitted on : Tuesday, March 24, 2020 - 3:32:58 PM
Last modification on : Saturday, March 28, 2020 - 1:25:46 AM
Long-term archiving on: : Thursday, June 25, 2020 - 2:04:14 PM

File

Med_generale_2019_Nyamankolly....
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-02517436, version 1

Collections

Citation

Elsa Nyamankolly. Devenir des personnes vivant avec le VIH sous une association TRIO dans la cohorte Aquitaine ANRS CO3 : vers une stratégie de simplification thérapeutique ?. Médecine humaine et pathologie. 2019. ⟨dumas-02517436⟩

Share

Metrics

Record views

39

Files downloads

1